Why is QGEN down?
Down 2% over five years while the S&P 500 rose 72%; up 24% in the past year.
- Its filed figures improved while the shares lagged the market.
The other side, how the business stands, and the timeline, for Pro members.
QGEN's Quality Score fell 2 points on Tue, Nov 10, to 12. Buying slipped from its highest in 20 days (3 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 2% over five years while the S&P 500 rose 72%; up 24% in the past year.
The other side, how the business stands, and the timeline, for Pro members.
| The chart | Stronger than 84% of stocks |
| Latest filing | 6-K, Nov 6 |
Tue Nov 17: Jefferies 17th Annual London Global…Investor conference · date confirmed.
2 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -1.0% on average, higher 1 of 4 times.
Above Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
QGEN is #34 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 34 |
Expected to report Wed Feb 3, after the close (in 85 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -0.2% | +0.1% | not yet |
| Aug 5, 2026 | +1.0% | -0.5% | +2.5% |
| May 6, 2026 | -2.3% | -2.7% | -5.0% |
Sales grew in five of the last seven years, to $2.1B in 2025. It made a profit in seven of the eight years.
RSI 68.7, MACD below signal, above both averages. Not scored.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
QGEN scores 12 today, which Breakaway calls Above Average. It is #34 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Down 2% over five years while the S&P 500 rose 72%; up 24% in the past year. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
QGEN scores 12 today, which Breakaway calls Above Average (11 to 14). That is #34 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind QGEN's 12.
Expected to report Wed Feb 3, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. QGEN closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.